BRIEF—Sandoz partners with Chinese firm to produce insulin biosimilars

US-based generics firm Sandoz has agreed a deal with Chinese insulin supplier Gan & Lee to produce biosimilar versions of insulins for type 1 and type 2 diabetes.

The commercialization and supply agreement aims at bringing to market biosimilar versions of glargine, lispro and aspart, the three top insulin medicines by sales.

Sandoz, a unit of Swiss firm Novartis, will be fully responsible for commercializing these medicines in the EU, USA, Switzerland, Japan, South Korea, Canada, Australia and New Zealand.

Gan & Lee will be responsible for manufacturing and development, with support from Sandoz.